Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Inventory (2022 - 2025)

Arcutis Biotherapeutics has reported Inventory over the past 4 years, most recently at $22.6 million for Q4 2025.

  • Quarterly results put Inventory at $22.6 million for Q4 2025, up 55.82% from a year ago — trailing twelve months through Dec 2025 was $22.6 million (up 55.82% YoY), and the annual figure for FY2025 was $22.6 million, up 55.82%.
  • Inventory for Q4 2025 was $22.6 million at Arcutis Biotherapeutics, up from $22.4 million in the prior quarter.
  • Over the last five years, Inventory for ARQT hit a ceiling of $22.6 million in Q4 2025 and a floor of $4.3 million in Q3 2022.
  • Median Inventory over the past 4 years was $13.9 million (2023), compared with a mean of $13.7 million.
  • Biggest five-year swings in Inventory: soared 223.03% in 2023 and later rose 0.73% in 2024.
  • Arcutis Biotherapeutics' Inventory stood at $7.5 million in 2022, then soared by 74.79% to $13.1 million in 2023, then grew by 10.6% to $14.5 million in 2024, then skyrocketed by 55.82% to $22.6 million in 2025.
  • The last three reported values for Inventory were $22.6 million (Q4 2025), $22.4 million (Q3 2025), and $16.3 million (Q2 2025) per Business Quant data.